Check-Cap Ltd. Announces $10M Registered Direct Offering
Check-Cap Ltd. Announces $10M Registered Direct Offering
ISFIYA, Israel, March 1, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 20,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to an aggregate of 15,000,000 of the Company's ordinary shares in a registered direct offering. Each ordinary share is being sold together with one warrant to purchase 0.75 ordinary share at a combined offering price of $0.50 per ordinary share and accompanying warrant. The warrants will have a term of five years following the date of issuance, be exercisable immediately and have an exercise price of $0.65 per ordinary share. The registered direct offering is expected to close on or about March 3, 2022, subject to satisfaction of customary closing conditions.
以色列ISFIYA 2022年3月1日电Check-Cap Ltd.(“公司”或“Check-Cap”)(纳斯达克代码：CHEK)，(纳斯达克代码：CHEKZ)是一家临床阶段医疗诊断公司，正在推进C-SCAN®的开发，这是第一种也是唯一一种对患者友好的、免准备的筛查测试，可以在息肉可能转化为结直肠癌之前发现它们。本公司今天宣布，已与数家机构及认可投资者就买卖本公司20,000,000股普通股及附随认股权证订立最终协议，以登记直接发售最多15,000,000股本公司普通股。每股普通股将与一份认股权证一起出售，以购买0.75股普通股，合并发行价为每股普通股0.50美元和随附的认股权证。认股权证的有效期为发行之日起5年，可立即行使，行使价为每股普通股0.65美元。登记的直接发行预计将在2022年3月3日左右结束，前提是满足惯常的结束条件。